quarter results. commercial to Thank I’m excited you, fourth Barry. share our
with ZYNRELEF. progress We continue to launching significant make
Then, I’ll unit updates On number oncology by with expand metrics our I’ll and X, to also reporting with with ZYNRELEF finish business. start presentation, a demand ASC. up my update our number slide related with to-date. on key our results start new commercial with highlights And the I’ll on care launch summarizing of During metrics. an hospitals volume ZYNRELEF
challenging in have impact continued of only leading number confidence and three become label indicators, the with initial two market FDA with we’ve a first will specific pain. incredible procedures been of indication Our which ZYNRELEF of gives COVID-XX. quarters made with launch the Nevertheless, eventually that progress us leader postoperative
approvals a gain IDNs represents rapid continue targeted formulary We ZYNRELEF and growth. at our pipeline rate. and to This hospitals for for
the of and by unique growth pleased accounts the number very also ordering growth excellent We’re the seeing importantly, we’re rates. and and reorder
on metrics the later on ZYNRELEF a addition, units presentation. of in quarterly volume in basis. demand seeing In share monthly the significant and for I’ll specifics we’re growth these all
gain As X million surgical procedures in procedures. to we announced FDA to expands indicated record of the team market X expansion procedures from significant the worked ZYNRELEF’s R&D million about approximately with in target time. label surgical December, This our
We are expanded with already surgeons. seeing with the of initial usage increased existing impact label ZYNRELEF this
with ended demand volume Since stocking inventory channel. meaningful inventory ZYNRELEF quarter third and time, unit made the distribution the through we’ve and that burning on progress expected, initial in we increases excess sales. that As based
has outstanding ZYNRELEF bundle. surgical the Finally, an increasing the done job our outside team for separate reimbursement
formulary end into is number XXX formulary number through XXth. let’s of This of has doubled October and dive details. progress the X than Slide highlights XXX ZYNRELEF making to February a Now, approvals. approvals At approvals. we grown formulary rapid that more the reported
And are that P&T are over adding hospital more actually making formularies delays resulted decisions, of to impressive, COVID. to Our P&T ZYNRELEF have considering the formulary. large committees XX% successful those of due accounts even number
will clearly effective the in busy resonating approvals accounts. to be with ZYNRELEF’s the standard are broader significant ZYNRELEF ZYNRELEF. review approved These key additional outstanding Importantly, over usage. to of quarter significant messages with pricing formulary by quarter. with opioid The label the remain versus the bupivacaine, end approvals P&T reimbursement continued value reduction most for combined very progress, care, by we ZYNRELEF’s proposition hours, drivers XXX are mid-December. formulary our with over reduction scheduled targeted and remainder clinical in the these When superior committees demonstrating XX% of the usage product the FDA first before The and our a strategy data growth led opportunity XX a of of pain unrestricted for create of unrestricted
formulary and help priority ZYNRELEF remain a establish for a team. approvals New critical our business key pipeline new commercial for us
XX institutions their Next, of for IDN targeting ZYNRELEF I ZYNRELEF wanted XX% systems to unrestricted or highlight key have ZYNRELEF. a to procedures. down integrated system-wide to networks new of Exparel their Thus with interchange use strategy delivery formularies. from for top in systems XXX nearly for added create therapeutic of to approvals IDNs, include far, These IDNs indicated opportunities
for indicated ZYNRELEF $XX and IDNs of these account an estimated addition, million In annual XXX,XXX XX procedures sales. Exparel
number switching with on based On to to Symphony from to to acquisition on with it’s to ordering our on looking standard XX% accounts slide a unique Their allows of IDNs of six With XX% ZYNRELEF’s success ZYNRELEF lasts the up are clinical during for XX the we not XX% Health who demonstrated of hours. the months the indication, data. the wholesale dollars price of care to work for actually IDNs based XX% Our rationale makers, XXXB first expanded cost superior savings indicated a product of decision cost procedures. has change number XX, are and bupivacaine savings that benchmarked results offering that millions level of EXPAREL. Exparel launch with us potential surprising is ZYNRELEF senior for based simple, evaluating save versus to label
up We in is of unique first XXX from launch. significant the of accounts ordering XXX ordering accounts, launch, which are traction with in the months with gaining ZYNRELEF months first six unique three
three years, competitor, of account Anjeso. next Anjeso ZYNRELEF’s X analgesics two past non-opioid during the over greater than times Xaracoll and COVID ordering closest have launched the During unique ZYNRELEF, era. the number is
this ZYNRELEF of of six first real experience strong is all patients. this reorder accounts the analysis. surgeons products their in having addition, greatest We XX% In has an four indication excellent are world with the benchmarked months, the percentage that during for reordering believe
results on only the hospital procedures feel our impact with considering three launches. the of began and addition, the are launch In initial we ZYNRELEF surge COVID indicated outstanding, in label the
are number for progress of grew over of ZYNRELEF highlights during to the first first number unique made we’ve ordering with expansion demand third a in that quarter. at ordering The ordering is has continued time in XXX% by ZYNRELEF the XX we accounts initial unit XXXX of end volume accounts the grown and demand number reports Slide ‘XX, in XXX and unique of the aggressive the underscored from number volume. quarter over the the through While unit quarter. key progress continue the our priority strong the last week. December ZYNRELEF of XXX end make strong, fourth results the accounts accounts to
in growth to December January. recognize the that it’s stunted important surge Omicron ZYNRELEF the and However,
of During COVID as unexpected months, elective surgical to earlier certainly news ZYNRELEF’s million these approximately policy patient we decisions, surge delays the This Barry, indication label described tests detrimental X pre-op positive by shortages. to customers mid-December, our with result which positive two in surgeries and in was faced received were expanded staff a procedures.
us, with Omicron significant a seen volume ZYNRELEF we’ve days. January the three from XX% COVID Fortunately, behind fewer surge and demand in in levels appears with increase increase February,
a the COVID inception results of sells ZYNRELEF’s to and SKU. finish for XXXX. of the sets been believe of the the XXX-milligram that quarter remainder for impact SKU strong of our our nearly price our milligram up expansion broad our launch the with of label twice XXX us Importantly, which for combined of indication stabilization of has the first volume XX% since product, the at We demand
the monthly our this basis. being ZYNRELEF’s prior fueled both, that I is significant indications. expanded growth portion On volume described large and the by We quarterly growth demand slide, on believe unit of a
prior FDA still used label XXX cases, of mid-December, surgeons if was using ZYNRELEF evidence asked in one Over and surveyed they to patients. had XX% and ZYNRELEF that expanded indication, only total to had XX% mid-January, percentage expansion orthopedic a the ZYNRELEF had in Then, use replacement grown using pulse conducted hip it of surgeons the month we the of prior surgeons As XX% THA. THA. were and in since with In procedures. the ZYNRELEF surgeons they approved TKA for survey their with of indicated used
XXX,XXX Importantly, to the one next months. to who XX% within over procedures not use there annually. are plan tried cases and three it note, Of those THA of have THA ZYNRELEF
how of allow illustration So, excellent accelerate expanded this to our an indication growth. us ZYNRELEF’s is will
we of of is One questions frequent on distribution channel. the the inventory level the receive most on
understand initial the reorder distribution both the inventory the a unit at units ASCs. We based orders level and are quarter and the ex-factory we SKUs. distribution distribution excess have we’ve unit volume, As hospitals XX to ended orders our rate better selling in based is progress we initial Ultimately, inventory, burning sales for reporting sales. time, third ex-factory drew are inventory meaning quarter of goal stocking unit centers, demand increases In demand XXX% that demand Fourth channel, on XXth, we’ve from February channel on with XXX-milligram $XXX,XXX we in stocking is net rate replenishing currently hospital or ZYNRELEF down and were made outstanding with channel. inventory, volume. Since reorder volume this inventory their a of through goal SKU which Through that expected, the as unit every meaningful the order sold on demand for have at towards ASC. demand XX% ZYNRELEF. to progress based to distribution made
market, still paid the without our In issued set ASC X, the meaningful settings ZYNRELEF indicated acquisition reorder ZYNRELEF CXXXX, indicating fourth with the separate expect rate rate since milligram beyond reach XX%, This to to effective the specific first the and channel. separate and expect CMS in We during XXXX. improvements respect under ASC XXX% for rate XXXX. in year costs quarter. end the for ZYNRELEF pass-through our where the ZYNRELEF the for is We’ve application ZYNRELEF the accounting reimbursement have With by section excess it of isn’t and This will typical reorder XXX volume. XXX the effective priorities inventory ex-factory the This years the for in milligram bundle -- setting XXX quarter, total patients expect observed customers January some would milligram XXX is already setting. of XX% hospital outpatient the milligram in a Medicare milligram reimbursement at currently hospital we reorder and of than it’s of all pass-through of target SKU, surprising on the the unit that the significant first in SKU distribution demand lives quarter, April ASCs. payment. be first ago. of status for early reimbursement of a and XX, slide may XXX outpatient reimbursed benefits even significant care payers. outpatient On in key on pass-through through and We’ve the tremendous lower seen care the doses. coverage new our We’ve improvements Exparel’s separate close based additional surgical separate already competitive the separately be across the setting surgical surgical for the advantage X, care be impact bundle ZYNRELEF quarter Medicaid million have more the three reimbursement commercial with some from covered the CMS results already C-code, for XXX outside the the obtained cases, pass-through XXXX. a bundle I’ll of on care, drug remainder utilizing reviewing procedures A to in since key reimbursement, reimbursement And will is our component pricing in strategy also period. hospital separate a outside payment expired
priority Our surgeons, -- demonstrating indication is will to orthopedic new earlier with include usage TKA for accomplished THA from patients. expanding for new procedures. is expanding even demonstrated growth. consistent top the also the to example existing alone leverage cases shared and I This be This by faster surgeon
an In surgical newly accounts we’re existing in usage formulary indicated addition, procedures. and with working allow to of all approval remove our restrictions with ZYNRELEF
per Finally, beginning therapeutic of procedures to both traction IDNs interchange for potentially to to switching by Exparel with ZYNRELEF hospitals to we’re revisit save dollars indicated millions gain and year.
the within actively recounts. practice. number or experience priority two support the outcomes with with larger evaluated from surgeons routinely is three increasing ordering by with usage a utilizing increase second we’re on accounts usage ZYNRELEF. to initially using of of accounts ordering Many their ZYNRELEF Our surgeons to their ZYNRELEF expanded excellent patients, Based
with momentum increase approach this to gaining We’re usage.
expand access gain to service accounts volume, our in to IDNs Increased priority ZYNRELEF. Our at converted and allows continue for new sales to growth our is to approvals pipeline once and our other targeted is third formulary hospitals. and reps are
Finally, we’ll year ASC incredible ZYNRELEF effective of for will Medicare ZYNRELEF. progress number significant and that the outside payment of of hospital outpatient confidence a optimistic the growth summary, which patients for receive pass-through setting continue remain status reimbursement April XXXX care a have In with setting be and of Xst. for to for gives indicators, maximize us We made separate leading our bundle surgical of that care. we we’ve ZYNRELEF will the
gears was and franchise. sales results patient solid with XX, screening the new marketplace in shift Significant the review quarter impact to remained COVID like with the our million. decreasing products of franchise of I’d and Now, another for fourth oncology Slide care the of cancer net $XX.X quarter CINV starts. fourth headwinds performance
towards model In and and oncology other value-based support generic products. biosimilar cheaper, care addition, contracts move practices oncology community CMS’s
slide excellent competitive that during XXXX. value On Finally, oncology competition. high specifically, dominated sales of believe cost our in generally stabilizing portfolio will XX, number net unit stabilized More CINV to markets being products XXXX, maintaining to We by were XX% pricing. recovery with a our CINVANTI or of levels. these headwinds of job demand aggressive number generic turnaround team sales did and XXXX we at an practices
addition, we in We In Program in poised growth our following growing XXXX. process the SUSTOL the we moderate of products for started believe implemented are Refresh XXXX.
XXXX in two is factors. and moderate Our SUSTOL key based for belief poised growth CINVANTI both, are that on
fosaprepitant much ended, make sales the $XX.XX and outpatient we’ll attractive in in separate First, improving CINVANTI reimbursement reimbursement Xst, January generic has hospital XXXX tailwinds decreased value average experience which more XXXX. as [$XX.XX] QX (sic) will to effective segment proposition reimbursement price in
reimbursement over past the has year. ASP Akynzeo in $XXX decreased IV addition, by In
both can CINVANTI. benefiting offer SUSTOL and they So, there’s less value
be $XX During shortage infusion CINV are XXXX, tailwind that we quarter only IV bag an as net range the is to bag. potential CINVANTI product our to A expect first of the in million. sales some need of million which NK-X benefits experiencing, $XX accounts the doesn’t IV the
of COVID. regimens. backlog a we be both in believe that is result HEC patients the there a and MEC as used majority can addition, In products oncology of And of
opportunity will these a both patients As system our new growth create new reenter products. treatment, the for patients for
Finally, to close overview strategy. I of commercial an Heron’s with wanted
strategy. We our components two primary have of
care. First leading acute company is in to establish a as Heron
As off with Barry growing is start, FDA a earlier, I the for despite our previously and described ZYNRELEF clearly label accelerate the headwinds it’s fast future. to in shared of our will agreement rapidly. which expansion ZYNRELEF growth indications, the
commercial targets. Finally, of the same This potentially the we’re PONV care in product in HTX-XXX quarter commercial to resources fourth add customer an enviable a our second to will product allow team XXXX. with and position optimize us acute for
is profitability strategy business. the second of care oncology commercial our The of growth maximize return component and of
stabilized have poised a and XXXX. for moderate generic competitive in sales market in are We growth
to important profitability In we’ve oncology products. care addition, maximize taken steps the of
reduce scale better is to step And That now reductions with support to first CINVANTI, for which and aligned prepared turn manufacturing Barry. a COGS will my resources completes XXXX. remarks, I’ll the over also invest expense larger savings. cost The significant in significantly we’ve back and maximizing call profitability our to
